From:

To: Sent: Subject: Narayana, Arvind </O=CEPHALON/OU=US01 ADMINISTRATIVE GROUP/CN=RECIPIENTS /CN=ANARAYAN> Thibodeau, Laurie 3/26/2008 7:48:42 PM FW: Nurses Advisory Board

Redacted - Privilege

----Original Message----From: Dayno, Jeffrey Sent: Monday, March 24, 2008 6:19 PM To: Floyd, Eric Cc: Narayana, Arvind; Levin, Penny Subject: RE: Nurses Advisory Board

Thanks Eric.

Arvind/Penny - FYI below and Eric and I are in agreement.

JMD

-----Original Message-----From: Floyd, Eric Sent: Monday, March 24, 2008 5:15 PM To: Dayno, Jeffrey Subject: RE: Nurses Advisory Board Importance: High

I agree with both Penny and Arvind's position. Do not discuss details of deaths, but rather focus on postmarketing reports and how we proactively address them.

Ε

----Original Message----From: Dayno, Jeffrey Sent: Monday, March 24, 2008 12:04 PM To: Floyd, Eric Subject: FW: Nurses Advisory Board

Eric - as per below, Arvind is confused about Penny's response because the MSLs are out there using slides that have the line item information on 3 of the cases. I do not feel he should be presenting the details of these cases at this point in time but we need an aligned approach for the organization. Please advise - thanks. JMD

----Original Message----From: Narayana, Arvind Sent: Wednesday, March 19, 2008 4:11 PM To: Levin, Penny; Beckhardt, Stacey; Dayno, Jeffrey Cc: Messina, John; Yeh, Helen; Thibodeau, Laurie Subject: RE: Nurses Advisory Board

PLAINTIFFS TRIAL EXHIBIT **P-19022_00001**

Dear Stacey,



----Original Message-----From: Levin, Penny Sent: Tuesday, March 11, 2008 7:35 AM To: Narayana, Arvind Cc: Floyd, Eric Subject: RE: Nurses Advisory Board

Arvind,

Can you please help me understand more about your plans with regard to item 4?

item 4. when did we agree to discuss the specifics of the deaths in public like this? We have always said do not get into the details of the cases at these meetings as it can come out of a meeting with a different story and we'll be just a few weeks away from Juergen presenting before the FDA AC. Wouldn't you continue with our philosophy of indicating there were postmarketing reports of deaths and serious AEs which led to root cause analyses indicating the causes were blah blah blah etc?

Many thanks, Penny

----Original Message----From: Narayana, Arvind Sent: Mon 3/10/2008 3:50 PM To: Levin, Penny; Thibodeau, Laurie; Yeh, Helen; Messina, John; Beckhardt, Stacey; Dayno, Jeffrey Subject: FW: Nurses Advisory Board

Team,

Redacted - Privilege

-----Original Message-----From: Beckhardt, Stacey Sent: Tuesday, March 04, 2008 3:39 PM To: Narayana, Arvind Subject: Nurses Advisory Board

Just confirming you will be attending our Ad Board on April 4-5 in Orlando. We would like you to present 3052 data as well as the noncancer BTP characteristics data.

Thanks. Stacey

Sent from my BlackBerry Wireless Handheld